Illumina, Inc. (NASDAQ:ILMN) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

Several other research analysts have also recently commented on ILMN. Barclays PLC reissued an “equal weight” rating and set a $150.00 target price on shares of Illumina in a research note on Wednesday, August 9th. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 target price for the company in a research note on Wednesday, August 9th. Cowen and Company reissued an “outperform” rating and set a $200.00 target price on shares of Illumina in a research note on Wednesday, August 2nd. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. Illumina presently has a consensus rating of “Hold” and an average target price of $177.01.

Shares of Illumina (NASDAQ ILMN) traded down 0.98% during midday trading on Thursday, hitting $189.32. The company had a trading volume of 882,072 shares. The firm has a market capitalization of $27.64 billion, a PE ratio of 37.99 and a beta of 0.83. The company has a 50-day moving average of $181.43 and a 200 day moving average of $174.88. Illumina has a 12 month low of $119.37 and a 12 month high of $199.95.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the previous year, the firm posted $0.86 EPS. Illumina’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts expect that Illumina will post $3.65 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) Rating Lowered to Sell at BidaskClub” was published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/20/illumina-inc-ilmn-rating-lowered-to-sell-at-bidaskclub.html.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $194.73, for a total transaction of $3,894,600.00. Following the completion of the sale, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $104,993,742.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $184.75, for a total value of $26,788.75. Following the sale, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The disclosure for this sale can be found here. Insiders sold a total of 154,010 shares of company stock valued at $27,840,615 over the last three months. Company insiders own 1.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ILMN. Nisa Investment Advisors LLC increased its stake in Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock valued at $1,056,000 after buying an additional 1,800 shares in the last quarter. State of Tennessee Treasury Department increased its stake in Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock valued at $16,697,000 after buying an additional 7,040 shares in the last quarter. Bank of Nova Scotia increased its stake in Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock valued at $14,710,000 after buying an additional 62,612 shares in the last quarter. Aberdeen Asset Management PLC UK increased its stake in Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock valued at $4,775,000 after buying an additional 2,158 shares in the last quarter. Finally, Columbus Circle Investors bought a new stake in Illumina during the first quarter valued at approximately $10,121,000. 93.91% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.